reports
Orthocell Ltd: 2 directors
Two Directors at Orthocell Ltd sold 1,570,618 shares at 0.479AUD. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Positive Pre-Clinical Results Using CelGro® in Anterior Cruciate Liga...
PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC) (“Orthocell” or the “Company”) is pleased to announce positive pre-clinical results using CelGro® collagen rope for Anterior Cruciate Ligament (ACL) reconstruction. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180204005104/en/ Figure 1 - An illustration depicting a ruptured ACL (Graphic: Business Wire) Orthocell Managing Director Paul Anderson said: “We are extremely exci...
Orthocell Secures New Patent for Suture-Less Repair of Soft Tissue
PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a further Australian patent for its CelGro® collagen medical device platform for soft tissue regeneration and repair applications. The patent entitled “Suture-less repair of soft tissue” provides additional important intellectual property to protect the CelGro® product platform. Orthocell Managing Director Paul Anderson said: “This is an important addition to ou...
Orthocell Granted European Tendon Regeneration Patent
PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a key European Patent. The patent is entitled ‘Culture medium, culturing method and use of tenocytes’ protecting the method of manufacturing tendon regeneration cells (Tenocytes) to form the Autologous Tenocyte Implantation (Ortho-ATI®) product. The patent expires in 2027 and provides additional important intellectual property (IP) to protect Orthocell’s tendon repair ap...
Orthocell Commences Treatment of Its 1,000th Patient
PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce that it has commenced treatment of its 1,000th patient, in its TGA licensed manufacturing facility using the Company’s proprietary tissue engineering process, developed in conjunction with Professor Minghao Zheng and the University of Western Australia. This marks a significant milestone in the Company’s history as it continues to clinically validate its market leading regenerative medicine...
Orthocell obtient le marquage CE pour CelGro®
PERTH, Australie--(BUSINESS WIRE)-- La société de médecine régénérative, Orthocell Limited (ASX : OCC, « Orthocell » ou la « Société ») se réjouit d’annoncer qu’elle a reçu l’approbation règlementaire européenne (marquage CE) pour son dispositif médical à base de collagène, CelGro®. CelGro®, destiné à une toute gamme de procédures de régénération des tissus mous et osseux dentaires, peut désormais être commercialisé et vendu dans l’Union européenne (UE). « L’approbation règlementaire européenne pour CelGro® marque une étape c...
Orthocell Receives CE Mark for CelGro®
PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce receipt of European regulatory approval (CE Mark) for its CelGro® collagen medical device. CelGro®, for a range of dental bone and soft tissue regeneration procedures, can now be marketed and sold within the European Union (EU). “European regulatory approval for CelGro® marks a major milestone for Orthocell as it enables commercial rollout in the lucrative dental bone and soft tiss...
Orthocell Appoints Surgical Specialties as Exclusive Distributor
PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has appointed Surgical Specialties Pty Ltd (Surgical Specialties) as its exclusive distributor in Australia and New Zealand for its world leading cell therapies for tendon regeneration (Ortho-ATI®) and cartilage regeneration (Ortho-ACI®). “Surgical Specialties is a leading distributor of innovative medical devices and one of the few local companies with its own national sales fo...
1st Patient Recruited in Orthocell Ortho-ATI® Shoulder Tendon Study
PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC) today announced that it has recruited and treated its first patient in a randomised, controlled clinical trial of Ortho-ATI® versus corticosteroid injection, for the treatment of rotator cuff tendinopathy and tear in the shoulder. Rotator cuff tendinopathy and tear (which manifests as severe shoulder pain) is a common and often difficult injury to treat and affects more than 50% of adults over 50 years of age. Rotator cuff injuries m...
Orthocell Announces Collaboration with Johnson & Johnson Innovation
PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited has today announced a research collaboration agreement with DePuy Synthes Products, Inc., part of the Johnson & Johnson Family of Companies, for its Ortho-ATI® stem cell approach for the regeneration of degenerate tendons and ligaments. The collaboration was facilitated by Johnson & Johnson Innovation. Ortho-ATI is a novel non-surgical approach to treat chronic treatment resistant tendon injuries that have a significant negative effect on pati...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Orthocell Receives Approval for Human Nerve Regeneration Study Using C...
PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell has been granted ethics approval for a human study examining the effectiveness of its CelGro® collagen medical device, to guide and promote nerve regeneration in severed peripheral nerves of the hand and upper limb. The primary objective of this study is to demonstrate the safety, tolerability and effectiveness of CelGro® when used as a conduit in the surgical repair of peripheral nerve injuries. The study will involve 20 patients who have suffered in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.